MX341076B - Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. - Google Patents

Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.

Info

Publication number
MX341076B
MX341076B MX2013011246A MX2013011246A MX341076B MX 341076 B MX341076 B MX 341076B MX 2013011246 A MX2013011246 A MX 2013011246A MX 2013011246 A MX2013011246 A MX 2013011246A MX 341076 B MX341076 B MX 341076B
Authority
MX
Mexico
Prior art keywords
stable formulations
antibodies
meurte
programmed
related treatments
Prior art date
Application number
MX2013011246A
Other languages
English (en)
Other versions
MX2013011246A (es
Inventor
Manoj K Sharma
Chakravarthy Nachu Narasimhan
Kevin James Gergich
Soonmo Peter Kang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46931903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341076(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2013011246A publication Critical patent/MX2013011246A/es
Publication of MX341076B publication Critical patent/MX341076B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se a una formulación estable liofilizada de un anticuerpo anti PD-1 humano, en donde la formulación se hace liofilizando una solución acuosa, caracterizada porque comprende: a) 25-100 mg/mL del anticuerpo anti-PD-1 humano; b) 70 mg/mL de sacarosa; c) 0.2mg/mL de polisorbato 80; y d) 10 mM de amortiguador de histidina a pH 5.0-pH 6.0, y en donde el anticuerpo comprende: i) una cadena ligera que comprende los residuos de aminoácidos 20 a 237 de la SEQ ID NO.: 36, y ii) una cadena pesada que comprende los residuos de aminoácidos 20 a 466 de la SEQ ID NO: 31.
MX2013011246A 2011-03-31 2012-03-29 Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. MX341076B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470121P 2011-03-31 2011-03-31
PCT/US2012/031063 WO2012135408A1 (en) 2011-03-31 2012-03-29 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments

Publications (2)

Publication Number Publication Date
MX2013011246A MX2013011246A (es) 2013-10-17
MX341076B true MX341076B (es) 2016-08-04

Family

ID=46931903

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011246A MX341076B (es) 2011-03-31 2012-03-29 Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.

Country Status (22)

Country Link
US (1) US9220776B2 (es)
EP (2) EP3398612A1 (es)
JP (1) JP6014116B2 (es)
KR (4) KR102614259B1 (es)
CN (2) CN107854439A (es)
AU (1) AU2012236479B2 (es)
CA (1) CA2830806C (es)
CY (1) CY1120359T1 (es)
DK (1) DK2691112T3 (es)
ES (1) ES2676205T3 (es)
HK (1) HK1256245A1 (es)
HR (1) HRP20181139T1 (es)
HU (1) HUE039209T2 (es)
LT (1) LT2691112T (es)
MX (1) MX341076B (es)
PL (1) PL2691112T3 (es)
PT (1) PT2691112T (es)
RS (1) RS57492B1 (es)
RU (2) RU2633509C2 (es)
SI (1) SI2691112T1 (es)
TR (1) TR201810298T4 (es)
WO (1) WO2012135408A1 (es)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2812028B2 (ja) 1991-11-11 1998-10-15 上村工業株式会社 錫又は錫・鉛合金めっき皮膜のフュージング処理方法
JP5191537B2 (ja) * 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
SI2415470T1 (sl) 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposomski sestavek
BRPI1010576A2 (pt) 2009-05-11 2016-03-15 Berg Biosystems Llc métodos para tratamento de distúrbios oncológicos usando transferidores epimetabólicos, moléculas intracelulares multidimensionais ou influenciadores ambientais.
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
CA2830806C (en) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
CN105612175B (zh) 2013-08-08 2023-05-09 赛腾制药 基于IL-15和IL-15Rαsushi结构域的调节因子
PT3030262T (pt) 2013-08-08 2019-12-11 Inst Gustave Roussy Igr Composição farmacêutica de associação
JP6586087B2 (ja) * 2013-08-20 2019-10-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
JP6623353B2 (ja) * 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US20150273033A1 (en) * 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
CN111167008A (zh) 2013-12-05 2020-05-19 免疫系统公司 利用射频电学膜击穿（rf-emb）的癌症免疫疗法
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
EP3084003A4 (en) 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
AU2015214404B2 (en) 2014-02-04 2020-10-01 Incyte Corporation Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer
WO2015119930A1 (en) 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
KR20170052569A (ko) * 2014-07-18 2017-05-12 어드박시스, 인크. 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
JP6986965B2 (ja) 2014-07-22 2021-12-22 アポロミクス インコーポレイテッド 抗ｐｄ−１抗体
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
WO2016022630A1 (en) 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AU2015360736A1 (en) 2014-12-09 2017-06-01 Merck Sharp & Dohme Corp. System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP6723249B2 (ja) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 軟部組織を切除するためのシステムおよび方法
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP6951248B2 (ja) 2015-03-04 2021-10-20 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
US11326211B2 (en) 2015-04-17 2022-05-10 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to PD-1 antagonists
BR112017023867A2 (pt) * 2015-05-07 2018-07-24 Novimmune Sa métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
BR112017025562A2 (pt) * 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX389834B (es) 2015-06-24 2025-03-20 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
CN106390115A (zh) * 2015-07-29 2017-02-15 上海君实生物医药科技股份有限公司 一种人源化单克隆抗体的稳定制剂
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106480022B (zh) * 2015-08-27 2020-07-10 杨光华 干涉片段及其应用
CN106480023B (zh) * 2015-08-27 2020-07-10 杨光华 干涉片段及其应用
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CA2995502A1 (en) * 2015-09-21 2017-03-30 Merck Sharp & Dohme Corp. Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
SG10201912943RA (en) 2015-10-02 2020-02-27 Symphogen As Anti-pd-1 antibodies and compositions
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
US10294299B2 (en) 2016-01-22 2019-05-21 MabQuest SA Immunological reagents
WO2017143150A1 (en) 2016-02-19 2017-08-24 City Of Hope Bi-specific aptamer
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
WO2018018018A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
EP3500299B1 (en) 2016-08-19 2023-12-13 BeiGene Switzerland GmbH Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
JP2019530706A (ja) 2016-10-14 2019-10-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 尿路上皮がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3541841B1 (en) 2016-11-18 2024-09-11 Les Laboratoires Servier Anti-pd-1 antibodies and compositions
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018115458A1 (en) 2016-12-23 2018-06-28 Virttu Biologics Limited Treatment of cancer
BR112019014187A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-pd-1
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
SG11201907753TA (en) 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2018162446A1 (en) * 2017-03-06 2018-09-13 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2018201028A1 (en) 2017-04-28 2018-11-01 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
US20200354453A1 (en) * 2017-05-02 2020-11-12 Merck Sharp & Dohme Corp. Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
KR20200006115A (ko) * 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
MY195465A (en) 2017-05-16 2023-01-25 Jiangsu Hengrui Medicine Co PD-L1 Antibody Pharmaceutical Composition and use Thereof
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
CN111107873A (zh) * 2017-09-05 2020-05-05 默沙东公司 用于降低生物制剂粘度的化合物
WO2019084418A1 (en) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER
WO2019085982A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团南京顺欣制药有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
SG11202007590TA (en) 2018-02-13 2020-09-29 Merck Sharp & Dohme Methods for treating cancer with anti-pd-1 antibodies
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
CA3099547A1 (en) * 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN120714023A (zh) 2018-06-20 2025-09-30 因赛特公司 抗pd-1抗体及其用途
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
CA3111066A1 (en) 2018-09-13 2020-03-19 Merck Sharp & Dohme Corp. Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
WO2020097141A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN113316458B (zh) * 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
AU2020235455A1 (en) 2019-03-08 2021-10-28 Oxford Genetics Limited Method of selecting for antibodies
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
CN120053667A (zh) 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP3986454A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CA3146138A1 (en) * 2019-08-07 2021-02-11 Yanghan LIU Formulation comprising anti-pd-1/her2 bispecific antibody, method for preparing same and use thereof
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
TW202135860A (zh) * 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
WO2021143767A1 (zh) * 2020-01-15 2021-07-22 信达生物制药(苏州)有限公司 结合pd-1和pd-l1的双特异性抗体的制剂及其用途
EP4093435A1 (en) 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN113456582B (zh) * 2020-03-30 2024-06-14 鲁南制药集团股份有限公司 重组人源化抗pd-1单克隆抗体的液体制剂
US20230250173A1 (en) 2020-07-01 2023-08-10 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
CN116368222A (zh) * 2020-07-21 2023-06-30 斯克里普斯研究学院 破坏cd28-唾液酸糖苷配体复合物以增强t细胞活化
EP4194551A4 (en) 2020-08-07 2024-08-28 Alteogen, Inc. PROCESS FOR PRODUCING RECOMBINANT HYALURONIDASE
WO2022049526A1 (en) 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
EP4284834A1 (en) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2022166947A1 (zh) * 2021-02-08 2022-08-11 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的制备方法及其用途
TW202307006A (zh) 2021-06-03 2023-02-16 美商表面腫瘤學公司 用抗ｃｄ３９抗體及派姆單抗治療癌症之方法
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2022268887A1 (en) 2021-06-23 2022-12-29 Formycon Ag Formulations of anti-pd1 antibodies
WO2023104910A1 (en) 2021-12-08 2023-06-15 Tessa Therapeutics Ltd. Treatment of lymphoma
CN119013044A (zh) * 2022-04-14 2024-11-22 百济神州瑞士有限责任公司 含有pd-1抗体的稳定高浓度氯化钠配制品及其使用方法
JP2026501288A (ja) 2022-12-21 2026-01-14 フォーマイコン アーゲー 抗ｐｄ１抗体の製剤
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
EP4665763A1 (en) 2023-02-16 2025-12-24 Sun Pharmaceutical Industries Limited Stable protein compositions of anti-pd1 antibody
WO2025034883A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025106905A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2025143921A1 (ko) * 2023-12-29 2025-07-03 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
AU2007229554A1 (en) 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
EP2114451A2 (en) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US20100286038A1 (en) 2007-09-21 2010-11-11 Valentyn Antochshuk Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
EP2307050A4 (en) * 2008-07-04 2012-07-25 Ono Pharmaceutical Co USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
TR201802935T4 (tr) 2008-09-19 2018-03-21 Pfizer Stabil sıvı antikor formülasyonu.
EP2362767B1 (en) * 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110256135A1 (en) 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
CA2830806C (en) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments

Also Published As

Publication number Publication date
CN107854439A (zh) 2018-03-30
KR20190116563A (ko) 2019-10-14
HUE039209T2 (hu) 2018-12-28
HRP20181139T1 (hr) 2018-09-21
MX2013011246A (es) 2013-10-17
AU2012236479A1 (en) 2013-09-26
RU2013148537A (ru) 2015-05-10
KR20210008149A (ko) 2021-01-20
RS57492B1 (sr) 2018-10-31
DK2691112T3 (en) 2018-07-30
SI2691112T1 (en) 2018-07-31
EP2691112A4 (en) 2014-12-03
US9220776B2 (en) 2015-12-29
RU2633509C2 (ru) 2017-10-12
KR20210101336A (ko) 2021-08-18
KR102614259B1 (ko) 2023-12-19
EP2691112B1 (en) 2018-05-23
AU2012236479B2 (en) 2016-10-20
CA2830806C (en) 2020-05-12
LT2691112T (lt) 2018-07-25
KR102031020B1 (ko) 2019-10-14
RU2015123476A (ru) 2015-10-20
CN103429264A (zh) 2013-12-04
KR102289394B1 (ko) 2021-08-13
RU2563346C2 (ru) 2015-09-20
HK1256245A1 (en) 2019-09-20
KR20140026434A (ko) 2014-03-05
PT2691112T (pt) 2018-07-10
EP3398612A1 (en) 2018-11-07
CY1120359T1 (el) 2019-07-10
JP6014116B2 (ja) 2016-10-25
ES2676205T3 (es) 2018-07-17
PL2691112T3 (pl) 2018-09-28
EP2691112A1 (en) 2014-02-05
US20140234296A1 (en) 2014-08-21
TR201810298T4 (tr) 2018-08-27
JP2014515017A (ja) 2014-06-26
CA2830806A1 (en) 2012-10-04
WO2012135408A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
TN2015000396A1 (en) Antibody drug conjugates
MX385575B (es) Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX384191B (es) Molecula de union al antigeno especifico para el tejido objetivo.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
MX2022012083A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
EA201400625A1 (ru) Антитела против pd-l1 и их применение
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2014163714A3 (en) Antibody drug conjugates
EA201400447A1 (ru) АНТИТЕЛА К CD1d
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
PH12015501360A1 (en) Bmp-6 antibodies
NZ724395A (en) Anti-pdgf-c antibodies
UA115305C2 (uk) Композиції hyr1-похідних і способи лікування ними

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration